Luveltamab tazevibulin
- Generic Name
- Luveltamab tazevibulin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children
Sutro Biopharma initiates REFRαME-P1 trial of Luvelta (luveltamab tazevibulin) for pediatric CBFA2T3::GLIS2 AML, aiming to assess efficacy and safety. Previously, Luvelta showed complete remission in 42% of pediatric patients with ≥5% blasts in compassionate use.
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with ...
Sutro Biopharma initiates REFRαME-P1, a registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 acute myeloid leukemia (AML), highlighting the potential to address unmet needs in cancer treatment.
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination
Luveltamab tazevibulin (luvelta) + bevacizumab showed 56% ORR in late-stage ovarian cancer at RP2D, with 35% overall response rate. No new safety signals were observed. Expansion at RP2D ongoing with 23 additional patients enrolled; data expected in H1 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath